Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer
Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer
复制标题
关键EGFR信号基因突变状态与II期结直肠癌预后的相关性研究
DOI：
10.2217/fon-2017-0040
复制
发表时间：
2017-07-01
期刊：
影响因子：
3.3
通讯作者：
Wang, Lei
中科院分区：
文献类型：
--
作者：
Li, Li;Ni, Bei-Bei;Wang, Lei
目的：探讨EGFR信号通路关键基因突变与未经化疗的II期结直肠癌患者预后的关系。材料和方法：对160例未经辅助化疗的II期结直肠癌根治术患者进行KRAS、NRAS、BRAF、PIK3CA突变和DNA错配修复缺陷的发生率评估。结果如下：KRAS、BRAF或PIK3CA突变与预后不良相关，而DNA错配修复缺陷状态与预后无关。结合这三个标志物，预测值对不良无进展生存期和总生存期的敏感性分别达到0.645（p = 0.002）和0.709（p = 0.001）。结论：了解II期结直肠癌中KRAS、BRAF或PIK3CA的突变状态，可显著提高结直肠癌诊断的准确性。
Aim: To investigate the relationship between mutations of key genes in the EGFR signaling pathway and the prognosis of stage II colorectal cancer patients without chemotherapy. Materials & methods: The incidence of KRAS, NRAS, BRAF, PIK3CA mutations and deficient DNA mismatch repair were assessed in 160 stage II colorectal cancer patients who had been treated by radical operation without adjuvant chemotherapy. Results: Mutations in KRAS, BRAF or PIK3CA were associated with poor prognosis, while the deficient DNA mismatch repair status was not associated with the prognosis. Combining these three markers, the sensitivity of the predicted value for poor progression-free survival and overall survival reached 0.645 (p = 0.002) and 0.709 (p = 0.001), respectively. Conclusion: Knowing the mutation status of KRAS, BRAF or PIK3CA in stage II colorectal cancer can significantly improve the accuracy of prognoses.